Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
MPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1...
Main Authors: | G.F. Ferraccioli, M. De Santis, G. Zizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-06-01
|
Series: | Reumatismo |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/469 |
Similar Items
-
Mycophenolate Mofetil in severe or methotrexate refractory localized scleroderma
by: Martini G, et al.
Published: (2008-09-01) -
GISEA: an Italian biological agents registry in rheumatology
by: F. Trotta, et al.
Published: (2011-11-01) -
Modifications of total synthesis of mycophenolic acid
by: Grzegorz Cholewinski, et al.
Published: (2018-02-01) -
Studies on mycophenolic acid and lignan chemistry
by: Knittel, Peter
Published: (2011) -
Anti-Vasculogenic Effect of Mycophenolic Acid
by: Go, Ellen Lao
Published: (2019)